The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaydale Regulatory News (HAYD)

Share Price Information for Haydale (HAYD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.46
Bid: 0.45
Ask: 0.47
Change: -0.019 (-4.13%)
Spread: 0.02 (4.444%)
Open: 0.46
High: 0.441
Low: 0.441
Prev. Close: 0.46
HAYD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Share Options

26 Apr 2023 15:06

RNS Number : 5832X
Haydale Graphene Industries PLC
26 April 2023
 

 

For immediate release

26 April 2023

 

Haydale Graphene Industries plc

 

("Haydale", "the Company" or the "Group")

 

Grant of share options

 

 

Haydale (AIM: HAYD), the global advanced materials group, announces that on 25 April 2023 the Company approved the following:

 

1. under the 2020 EMI Scheme ("2020 EMI Scheme"), the grant of options to staff of the Group, over an aggregate 1,750,000 ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"); and

2. under the Haydale Technologies, Inc ("HTI") Stock Appreciation Rights Plan 2020 ("2020 SAR"), the grant of stock appreciation rights ("Stock Appreciation Rights") to an employee of the Group's wholly owned US subsidiary, HTI, over an aggregate 1,000,000 Ordinary Shares.

(The 2020 EMI Scheme and the 2020 SAR , together the "Share Schemes". The new Options or Stock Appreciation Rights granted under the Share Schemes, together the "April 2023 Grants"). The April 2023 Grants represents approximately 0.35% of the Company's issued ordinary share capital.

 

Background to the April 2023 Grants

 

The Company adopted the Share Schemes to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. The Share Schemes have certain performance criteria to ensure that value is created for shareholders before any value is delivered to Directors and key staff. The April 2023 Grants will extend the options to those that have joined since the previous grant of Options in November 2022. 

 

Terms of the April 2023 Grants

 

All of the April 2023 Grants have an exercise price of 2.25p per Ordinary Share (being a 42% premium to the closing mid-market price of the Company's Ordinary Shares on 25 April 2023, (the day of the approval of the April 2023 Grants) and can only be exercised between the third and tenth anniversary of the awards. The proportion of the awards made by the April 2023 Grants that are capable of vesting is dependent on certain performance criteria, directly linked to the performance of the Company's share price over the period to 30 September 2026 as follows:

 

% of April 2023 Grants subject to the Performance Condition

 

Performance Condition

 

30%

For a period of 15 consecutive dealing days, commencing after the date of the April 2023 Grants and ending on or before the 30 September 2024, the closing price of the Ordinary Shares exceeds 4p (four) per Ordinary Share.

 

30%

For a period of 15 consecutive dealing days, commencing after the date of the April 2023 Grants and ending on or before the 30 September 2025, the closing price of the Ordinary Shares exceeds 6p (six) per Ordinary Share.

 

40%

For a period of 15 consecutive dealing days, commencing after the date of the April 2023 Grants and ending on or before the 30 September 2026, the closing price of the Ordinary Shares exceeds 8p (eight) per Ordinary Share.

 

There are no other vesting criteria for the April 2023 Grants. If the share price does not reach the target price by their respective dates, that portion of the award will lapse.

 

The Company's Remuneration Committee retains the ability to amend the performance conditions for the April 2023 Grants and for future grants to ensure that such grants achieve the stated purpose.

 

Following the April 2023 Grants, the Company's total number of Options and SARs outstanding as at the date of this announcement is 101,775,000 representing approximately 12.95% of the Company's existing issued share capital and 9.90% on a fully diluted basis including all outstanding warrants.

 

The number of Ordinary Shares currently in issue is 785,852,475 and it is this number that has been used to calculate the above percentage shareholdings.

 

 

For further information:

Haydale Graphene Industries plc

David Banks, Non-Executive Chair

Tel: +44 (0) 1269 842 946

 

www.haydale.com 

finnCap (Nominated Adviser & Broker)

 

Julian Blunt/Edward Whiley, Corporate Finance

Andrew Burdis, ECM

Tel: +44 (0) 20 7220 0500 

 

 

Notes to Editors

 

Haydale is a global technologies and materials group that facilitates the integration of graphene and other nanomaterials into the next generation of commercial technologies and industrial materials. With expertise in graphene, silicon carbide and other nanomaterials, Haydale is able to deliver improvements in electrical, thermal and mechanical properties, as well as toughness. Haydale has granted patents for its technologies in Europe, USA, Australia, Japan and China and operates from six sites in the UK, USA and the Far East.

 

For more information please visit: www.haydale.com

Twitter: @haydalegraphene

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHNKABKQBKDQQB
Date   Source Headline
23rd Dec 20167:00 amRNSIssue of Shares
15th Dec 20163:00 pmRNSResult of AGM
15th Dec 20167:00 amRNSAGM Statement
28th Nov 20167:00 amRNSAgreement with Huntsman Advanced Materials
22nd Nov 20167:00 amRNSAnnual Financial Report
19th Oct 20167:00 amRNSPDMR Dealings
18th Oct 20167:00 amRNSPDMR Dealings
17th Oct 20167:00 amRNSGrant of Options
13th Oct 20167:00 amRNSDistribution Agreement
13th Oct 20167:00 amRNSPDMR Dealings
11th Oct 20167:00 amRNSResult of Open Offer and Total Voting Rights
28th Sep 20167:00 amRNSContract Extension
23rd Sep 201610:57 amRNSResult of Placing
23rd Sep 20167:01 amRNSFinal Results
23rd Sep 20167:00 amRNSProposed Acquisition and Fundraise
9th Sep 20164:05 pmRNSCompletion of Innophene Acquisition
26th Aug 20167:00 amRNSDirector/PDMR Shareholding
25th Aug 20167:00 amRNSAcquisition and Issue of Equity
11th Aug 20167:00 amRNSGraphene Enhanced PLA Filaments for 3D Printing
8th Aug 20167:00 amRNSHaydale Funds New Professorial Chair Within WCPC
29th Jul 20167:00 amRNSBoard Change
7th Jun 201610:42 amRNSGrant of Warrants
26th May 20167:00 amRNSAgreement with Flowtite Technology AS
20th May 20163:27 pmRNSDirector Dealing
20th May 20167:00 amRNSGrant of Options
18th May 20167:00 amRNSReactor Supply and Collaboration Agreement
9th May 20167:00 amRNSInvestor Open Day
25th Apr 20164:40 pmRNSHolding(s) in Company
7th Apr 201611:28 amRNSCorrection: Joint Development & Supply Agreement
7th Apr 20167:00 amRNSJoint Development and Supply Agreement
22nd Mar 20167:00 amRNSHalf Yearly Report
14th Mar 20167:00 amRNSGraphene Enhanced Composite Products Launched
8th Mar 201611:12 amRNSNotice of Results
16th Feb 20167:00 amRNSGrant Awards
4th Feb 20167:00 amRNSHaydale Commission Composite Pipe Testing Facility
3rd Feb 20167:00 amRNSAcquisition of Rights and Grant of Warrants
3rd Dec 201511:58 amRNSResult of AGM
1st Dec 201512:05 pmRNSDirector Dealing
26th Nov 20157:00 amRNSHolding(s) in Company
25th Nov 20157:00 amRNSHolding(s) in Company
23rd Nov 201510:50 amRNSResults of General Meeting
20th Nov 20151:14 pmRNSResult of Open Offer
17th Nov 20157:00 amRNSGrant Awards
10th Nov 201511:32 amRNSNotice of AGM
6th Nov 20154:45 pmRNSPosting of Open Offer Application Forms
2nd Nov 201512:50 pmRNSDirector/PDMR Shareholding
2nd Nov 20157:01 amRNSIssue of Equity
2nd Nov 20157:00 amRNSFinal Results
14th Oct 20157:00 amRNSEuropean Patent Grant
1st Oct 20157:00 amRNSAgreement with Scott Bader Company Ltd

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.